Adverse Events Following Lymph Node Dissection for Cutaneous Malignant Melanoma: Can We Do Better?
Treatment advances for cutaneous malignant melanoma significantly improved overall survival, estimated at 91% and 89% at 5 and 10 years, respectively. Disease stage remains the most important predictor of outcomes and complete surgical resection offers the best chance of cure. Lymph node dissection (LND) is the current standard of treatment and allows controlling regional involvement in melanoma patients. Several studies have reported varying rates of local and systemic complications associated with LND. However, these studies use a variety of definitions and grading systems, and vary in quality leading to inconsistent results. This study will first, characterize, homogenize, grade and quantify the local and systemic complications associated with LND in cutaneous melanoma patients by conducing a systematic literature review, and second, quantify the incidence of adverse events associated with LND in melanoma patients.